In 147 people with HIV and obesity on an integrase inhibitor plus TAF/FTC, switching to doravirine with TAF/FTC or TDF/FTC did not produce clinically meaningful differences in weight change at 48 weeks (difference 1.36 and -0.89 percentage points) or metabolic health.
RCTn = 147
Koethe et al. A 48-Week, Randomized Controlled Trial of Doravirine for Individuals With HIV and Obesity on Integrase Inhibitors and Tenofovir Alafenamide: The Do IT Study (ACTG A5391)